Clik here to view.
Harbour BioMed Enters Agreement to Develop Fully Human Antibody Fragments for...
SHANGHAI & ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. Harbour BioMed announced today that it has entered into an agreement with ImmunoChina Pharmaceuticals Co. Ltd. to develop fully human...
View ArticleClik here to view.
PremasとIncellDxがインドでの販売契約を締結
ニューデリー （ビジネスワイヤ） — Premas Life Sciences Pvt., Ltd.とIncellDx,...
View ArticleClik here to view.
Premas与IncellDx签署印度经销协议
新德里 (美国商业资讯) — Premas Life Sciences Pvt., Ltd.与IncellDx, Inc.今天宣布签署一份排他性经销协议。该商业伙伴关系提供了单细胞多份诊断试剂的功效，现在可采用流式细胞计数仪，分析实体瘤癌症的分子及蛋白质标记。协议内容包括：IncellDx的专利单细胞检测，用于肿瘤细胞和免疫细胞亚型上PD-L1的定量；专利单细胞检测，用于检测宫颈样本中的HPV...
View ArticleClik here to view.
Changes in Executive Management at Sosei
TOKYO & LONDON Sosei Group Corporation (“Sosei” or the “Company”) (TOKYO: 4565), the world leader in GPCR medicine design and development, today announced that Dr. Fiona Marshall has resigned...
View ArticleClik here to view.
SymBio Pharmaceuticals: Initiation of Phase I Clinical Trial for Oral...
TOKYO SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”) (JASDAQ: 4582) announced today that it has initiated a Phase 1 study in Japan for oral TREAKISYM® in patients with progressive...
View ArticleClik here to view.
シンバイオ製薬：進行性固形がんを対象としたトレアキシン®経口剤の第Ⅰ相臨床試験の開始のお知らせ
東京 （ビジネスワイヤ） — シンバイオ製薬株式会社（本社：東京都、以下「シンバイオ」） (JASDAQ: 4582) は、この度、トレアキシン®経口剤の開発について、進行性固形がんを対象とした第Ⅰ相臨床試験（以下「本試験」）を開始したことをお知らせします。...
View ArticleClik here to view.
和铂医药完成A+轮融资，加速临床项目开发和公司业务发展
中国上海、荷兰鹿特丹、美国马萨诸塞州剑桥 和铂医药今天宣布完成A+轮融资，以加速公司总体业务发展，尤其是公司已有临床阶段项目的开发。本轮融资由中国顶级的投资机构鼎晖投资领投，A轮投资机构尚珹资本参与了本轮融资。财务细节未予以公布。 “在和铂医药成立的第一年内，和铂团队成功地完成了对于荷兰抗体平台公司Harbour...
View ArticleClik here to view.
Harbour BioMed Completes Series A+ Round Financing to Accelerate the...
SHANGHAI & ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. Harbour BioMed announced today that it has completed a Series A+ round financing to accelerate its growth, especially the development...
View ArticleClik here to view.
European Commission Approves ADCETRIS® (brentuximab vedotin) for...
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC)...
View ArticleClik here to view.
武田薬品：「世界で最も持続可能な100社」に3年連続で選出
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（東証：4502）は、このたび、カナダの出版社であるCorporate Knights社が選定する2018年版「世界で最も持続可能な100社（2018 Global 100 Most Sustainable Corporations in the World Index、以下、「Global...
View ArticleClik here to view.
Takeda Recognized as a Global 100 Most Sustainable Corporation for Third...
OSAKA, Japan Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to be named by Corporate Knights as one of the 2018 Global 100 Most Sustainable Corporations in the World (Global...
View ArticleClik here to view.
武田连续第三年入选全球最具可持续性企业百强
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited)[TOKYO:4502](“Takeda”)今年第三年被Corporate...
View ArticleClik here to view.
欧盟委员会核准ADCETRIS® (brentuximab...
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，欧盟委员会(EC)延长了现有的ADCETRIS® (brentuximab...
View ArticleClik here to view.
欧州委員会がアドセトリス（ブレンツキシマブ・ベドチン）を過去に1種類の全身療法を受けているCD30陽性皮膚T細胞リンパ腫の治療薬として承認することで、患者...
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社(TSE:...
View ArticleClik here to view.
Takeda’s Zika Vaccine Candidate Receives U.S. FDA Fast Track Designation
OSAKA, Japan Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAK-426, Takeda’s...
View ArticleClik here to view.
Aravive Biologics and WuXi Biologics to Form Strategic Manufacturing...
HOUSTON & WUXI, China Aravive Biologics, Inc. and WuXi Biologics (WuXi Bio, 02269.HK) today announced plans to expand their biologics manufacturing collaboration, based on the rapid success...
View ArticleClik here to view.
Astellas Reports Financial Results for the First Nine Months of FY2017
TOKYO Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the financial results for the first nine months of fiscal year 2017 ending March 31, 2018...
View ArticleClik here to view.
武田的寨卡候选疫苗进入美国FDA快通道审理
日本大阪 (美国商业资讯) — 武田药品工业株式会社[TSE: 4502]（以下简称“武田”）今天宣布，武田的纯化、灭活、铝佐剂、全寨卡病毒候选疫苗TAK-426进入美国食品药品管理局(FDA)快通道审理。...
View ArticleClik here to view.
世界最大級のナノテクノロジー総合展が開催！「nano tech 2018 国際ナノテクノロジー総合展・技術会議」超スマート社会（Society...
東京 （ビジネスワイヤ） — nano tech 実行委員会/株式会社JTBコミュニケーションデザインは、2018年2月14日～16日の3日間 東京ビッグサイトにて、世界最大級のナノテクノロジーの展示会「nano tech 2018...
View ArticleClik here to view.
nano tech 2018, the International Nanotechnology Exhibition & Conference,...
TOKYO This year marks the 17th edition of nano tech, the world’s premier nanotechnology exhibition. Five hundred organizations from 24 countries and regions are exhibiting this year, in 750 booth...
View Article